Prellis Biologics Appoints New CEO, Raises $35 Million in Se

Former Generate Biomedicines, Amgen and Novartis senior leader Mike Nohaile joins Prellis as CEOSAN FRANCISCO--(BUSINESS WIRE)--Prellis Biologics, Inc (Prellis Bio), a biotherapeutics company, today appointed Michael Nohaile, PhD as its new CEO and announced it has raised a $35 million Series C funding round, co-led...

Related Keywords

India , Dallas , Texas , United States , Israel , Melanie Matheu , Mike Nohaile , James Rothman , Prellis Bio , Michael Nohaile , Michael Marks , Amgen , Prellis Biologics Inc , Prellis Biologics Inc Bio , Novartis , Lucas Venture Group , Bristol Myers Squibb , Johnson , Intel , Former Generate Biomedicines , Prellis Biologics , Celesta Capital , Avidity Partners , Khosla Ventures , True Ventures , Lucas Venture , Generate Biomedicines , Chief Technology Officer , Externalized Human Immune System , Chief Scientific Officer , Global Head , Molecular Diagnostics , Lymph Node Organoids , Lei Meng , Senior Therapeutics Analyst , Nobel Prize , Sterling Professor , Cell Biology , Prellis Bio Board Chairman , Founding Managing Partner , Bristol Myers , Externalized Immune System , San Francisco Bay Area ,